This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While the numbers increase, still the debate between SAVR and TAVR is riddled with speculation, skepticism, and absolute confidence. Expected to improve with polymer valves) The latest trial to join the litereture is EARLY TAVR in October 2024 Here is a brief, personal comment about the paper for non-academic consumption.
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).
“It is going to be an exciting time for JACC: Case Reports to build on a team of multidisciplinary cardiovascular practitioners with diverse backgrounds and experiences, and at different stages of their professional careers, to enhance the journal’s academic and educational impact globally.”
A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.
Transcarotid transcatheter aortic valve replacement (TC-TAVR) has emerged as an alternative access in suboptimal transfemoral candidates, but no data exist comparing TC-TAVR and SAVR. At 30 days, the SAVR group showed a higher rate of the primary composite outcome compared with the TC-TAVR group (12.6% andP=0.001, respectively).
Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.
“It is going to be an exciting time for JACC: Case Reports to build on a team of multidisciplinary cardiovascular practitioners with diverse backgrounds and experiences, and at different stages of their professional careers, to enhance the journal’s academic and educational impact globally.”
The primary efficacy end point is the incidence of bleeding events, defined by the VARC3 (Valve Academic Research Consortium3) criteria, at 1year postrandomization. The primary safety end point is a composite of cardiac death, myocardial infarction, and ischemic stroke at 1 year.
Reviewing NOTION study, the Nordic TAVI 10 year follow up has just been released (Ref 1) : Caution : Non-academic content This study reports the long-term outcome in low-risk individuals who required AVR. Now, some academic queries ? No doubt ,the Aortic interventional world is applauding and everyone is joining the party.
TAVR) or quality studies, and forecast case volumes and inventory/resource needs. Intelligent AI-driven Workflow ASCEND’s AI-driven image viewer, InView, provides an intelligent, highly effective solution for echo, vascular and cath reading and reporting.
SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR). A total of 716 patients underwent TAVR with either a self-expanding supraannular valve or a balloon-expandable valve.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content